Skip to main content

Table 1 Baseline characteristics of randomized participants [6]

From: Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial

Characteristic

Study populationa (N = 27)

Age, years, mean (SD)

24.5 (8.1)

Sex, male, n (%)

17 (63)

Ethnic origin, n (%)

 Māori

4 (15)

 New Zealand European

20 (74)

 Other

3 (11)

History of allergic rhinitis, n (%)

14 (51.9)

BMI, kg/m2, mean (SD)

24.6 (3.5)

FEV1b, % predicted, mean (SD)

87.7 (10.6)

PEF, L/min, mean (SD)

443 (99)

FeNO, ppb, median (range)

87 (42–212)

Blood eosinophil count, × 109/L, median (range)

0.33 (0.18–1.18)

Blood eosinophil count ≥ 0.27 × 109/L, n (%)

24 (88.9)

Serum periostin, ng/ml, median (range)

187.5 (109.4–442.5)

  1. BMI, body mass index; FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; PEF, peak expiratory flow; ppb, parts per billion; SD, standard deviation
  2. aIncludes all participants who were randomized to primary analysis; 26 participants provided serum samples. bBefore bronchodilation